ROIV
Roivant Sciences Ltd
NASDAQ: ROIV · HEALTHCARE · BIOTECHNOLOGY
$28.56
+0.99% today
Updated 2026-05-08
Market cap
$20.24B
P/E ratio
—
P/S ratio
1,520.66x
EPS (TTM)
$-1.17
Dividend yield
—
52W range
$11 – $30
Volume
5.4M
WallStSmart proprietary scores
24
out of 100
Grade: F
Strong Sell
Investment rating
2.0
Growth
F9.0
Quality
A+2.5
Profitability
F5.0
Valuation
C+5/9
Piotroski F-Score
Moderate
12.9
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →195 stocks currently score above 75
Price targets
Analyst target
$35.67
+24.89%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy10 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 12.89 — safe zone
+ Debt/equity 0.05x — low leverage
Risks
- Thin margins at 0.00%
- Negative free cash flow $-201.42M
- Revenue declining -77.80% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $55.29M | $61.28M | $32.71M | $29.05M | $13.31M | $0.0B |
| Net income | $-845.26M | $-1.01B | $4.35B | $-171.98M | $-265.89M | — |
| EPS | — | — | — | — | $-1.17 | $-1.23 |
| Free cash flow | $-695.16M | $-856.08M | $-766.65M | $-844.05M | $-201.42M | — |
| Profit margin | -1,528.89% | -1,646.59% | 13,294.18% | -591.96% | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-20 | VENKER, ERIC | Sale | 200,000 | — |
| 2026-04-20 | VENKER, ERIC | Buy | 200,000 | $3.85 |
| 2026-04-20 | PULIK, RICHARD | Buy | 84,026 | — |
Peer comparison
Smart narrative
Roivant Sciences Ltd trades at $28.56. Our Smart Value Score of 24/100 indicates the stock is weak. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 12.89, it sits in the safe zone. TTM revenue stands at $13.31M.
Frequently asked questions
What is Roivant Sciences Ltd's stock price?
Roivant Sciences Ltd (ROIV) trades at $28.56.
Is Roivant Sciences Ltd overvalued?
Smart Value Score 24/100 (Grade F, Strong Sell).
What is the price target of Roivant Sciences Ltd (ROIV)?
The analyst target price is $35.67, representing +24.9% upside from the current price of $28.56.
What is the future stock price of ROIV by 2030?
Our research-backed model estimates Roivant Sciences Ltd could reach $22.30 by 2030, based on analyst consensus, management guidance, and sector analysis.
What is Roivant Sciences Ltd's revenue?
TTM revenue is $13.31M.
Piotroski F-Score?
5/9 — moderate financial health.
Altman Z-Score?
12.89 — safe zone.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1,520.66x
ROE-19.10%
Beta1.14
50D MA$28.33
200D MA$20.96
Shares out0.72B
Float0.53B
Short ratio—
Avg volume5.4M
Performance
1 week+1.62%
1 month-0.70%
3 months+9.53%
YTD+30.32%
1 year—
3 years—
5 years—